Este sitio web utiliza tecnologías de seguimiento, como cookies, para brindar una mejor experiencia al usuario. Si continúa utilizando este sitio, entonces reconoce nuestro uso de tecnologías de seguimiento. Para obtener información adicional, consulte nuestra Política de Privacidad.
An important aspect of the immune system’s protective power is its ability to tell the difference between “self” and “non-self” cells. However, in cancer this line between normal, healthy cells and tumor cells becomes blurred and sometimes allows tumors to escape immune recognition. Therefore, Dr. Megan Ruhland aims to advance our understanding of this process so that we can develop ways to address it. Specifically, her team has developed a model that will allow her to track immune cells and their engagements during normal tissue homeostasis as well as during the development of lung cancer. This knowledge could then provide new targets for immunotherapy that enable the immune system to reject tumors in the same way it eliminates invaders like viruses or bacteria.
University of California, San Francisco | All Cancers | 2017 | Matthew F. Krummel, Ph.D.
*Los resultados de la inmunoterapia pueden variar de un paciente a otro.
Comuníquese con nosotros
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Directorio de Personal
This Skin Cancer Awareness month, discover new research, treatments, and progress for a future immune to skin cancer.
Birdies & Brews mixes beer and golf while raising funds for cancer immunotherapy research.